OBJECTIVES: To develop an immunoassay for osteopontin (OPN), a secreted phosphoglycoprotein that is implicated in a number of human diseases, and establish basal plasma OPN levels in healthy women. DESIGN AND METHODS: An antigen-capture ELISA was developed to quantity OPN in plasma using a combination of mouse monoclonal and rabbit polyclonal antibodies. Basal OPN levels were determined in blood plasma of 21 pre- and 14 postmenopausal women obtained at 7-day intervals over a 4-week period. RESULTS: A group of 35 healthy women had a median OPN level of 31 micrograms/L (range = 14-64 micrograms/L). Comparison between pre- and postmenopausal women showed that their 4-week average OPN levels did not differ significantly (p > 0.16, Mann-Whitney test), and that levels in each premenopausal individual remained constant during the menstrual cycle, unaffected by cyclical levels of leuteinizing hormone and progesterone. CONCLUSION: Systematic quantification of plasma OPN can now be done by ELISA, which was used to establish basal plasma OPN levels in a group of healthy women. Levels in pre- and postmenopausal women appeared relatively stable over a 4-week period.
OBJECTIVES: To develop an immunoassay for osteopontin (OPN), a secreted phosphoglycoprotein that is implicated in a number of human diseases, and establish basal plasma OPN levels in healthy women. DESIGN AND METHODS: An antigen-capture ELISA was developed to quantity OPN in plasma using a combination of mouse monoclonal and rabbit polyclonal antibodies. Basal OPN levels were determined in blood plasma of 21 pre- and 14 postmenopausal women obtained at 7-day intervals over a 4-week period. RESULTS: A group of 35 healthy women had a median OPN level of 31 micrograms/L (range = 14-64 micrograms/L). Comparison between pre- and postmenopausal women showed that their 4-week average OPN levels did not differ significantly (p > 0.16, Mann-Whitney test), and that levels in each premenopausal individual remained constant during the menstrual cycle, unaffected by cyclical levels of leuteinizing hormone and progesterone. CONCLUSION: Systematic quantification of plasma OPN can now be done by ELISA, which was used to establish basal plasma OPN levels in a group of healthy women. Levels in pre- and postmenopausal women appeared relatively stable over a 4-week period.
Authors: Pieter H Anborgh; Laura Br Caria; Ann F Chambers; Alan B Tuck; Larry W Stitt; Muriel Brackstone Journal: Am J Transl Res Date: 2015-04-15 Impact factor: 4.060
Authors: Praveen Srungaram; Jody A Rule; He Jun Yuan; Andreas Reimold; Benny Dahl; Corron Sanders; William M Lee Journal: Cytokine Date: 2015-03-21 Impact factor: 3.861
Authors: Alka Jain; Dianalee A McKnight; Larry W Fisher; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin; Neal S Fedarko Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: David T Denhardt; Devra Mistretta; Ann F Chambers; Shuba Krishna; Joseph F Porter; Srilatha Raghuram; Susan R Rittling Journal: Clin Exp Metastasis Date: 2003 Impact factor: 5.150
Authors: Dympna Harmey; Lovisa Hessle; Sonoko Narisawa; Kristen A Johnson; Robert Terkeltaub; José Luis Millán Journal: Am J Pathol Date: 2004-04 Impact factor: 4.307